Safety of apixaban compared to warfarin in hemodialysis patients: Do antiplatelets make a difference?

Abstract

Apixaban is associated with less bleeding in HD patients compared to warfarin, but concomitant antiplatelet use may negate the safety advantage. Prospective trials are warranted to determine the impact of antiplatelets on apixaban safety.